Scholarly Index
Wee Joo Chng
National University Cancer Institute, Singapore; 34,284 total citations; 674 total publications; best world rank #77
National University Cancer Institute, Singapore
34,284Total citations
674Total publications
83H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Multiple Myeloma Research and Treatments | Lifetime | 78 | SG 1 | 99.45 |
| Protein Degradation and Inhibitors | Lifetime | 77 | SG 1 | 99.28 |
| Peptidase Inhibition and Analysis | Lifetime | 314 | SG 3 | 98.72 |
| Ubiquitin and proteasome pathways | Lifetime | 339 | SG 2 | 98.40 |
| Cancer Mechanisms and Therapy | Lifetime | 185 | SG 3 | 97.98 |
| Histone Deacetylase Inhibitors Research | Lifetime | 338 | SG 2 | 96.81 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 996 | SG 5 | 93.35 |
| Protein Tyrosine Phosphatases | Lifetime | 391 | SG 4 | 92.43 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 938 | SG 1 | 91.61 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 97 | SG 1 | 98.68 |
| Protein Degradation and Inhibitors | 2021-2025 | 124 | SG 1 | 97.15 |
| Peptidase Inhibition and Analysis | 2021-2025 | 183 | SG 1 | 95.86 |
| Cancer Mechanisms and Therapy | 2021-2025 | 104 | SG 2 | 92.98 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 622 | SG 1 | 87.23 |
| Ubiquitin and proteasome pathways | 2021-2025 | 723 | SG 3 | 84.14 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 618 | SG 2 | 80.39 |